USP Abacavir and Lamivudine Tablets - Assay (Standard Solution)
LC Conditions
Column
Kinetex 2.6 µm EVO C18 100 Å, LC Column 100 x 4.6 mm, EA
Brand
Kinetex
Part No
00D-4725-E0
Phase Name
EVO C18
Elution Type
Gradient
Mobile Phase
A: Water and TFA (2000:1)
B: Acetonitrile, Methanol and TFA (1000:1000:1)
Gradient Profile
Step No.
Time(min)
%A
%B
1
0
100
0
2
1.98
100
0
3
5.94
70
30
4
5.99
40
60
5
6.49
40
60
6
6.54
100
0
7
13
100
0
Flow Rate
1.50 mL/min
Temperature
40°C
System
Agilent Technologies 1200 Series Agilent Technologies 1200 Series
Detection
LC/UV (DAD, PDA) @ 270 nm (nanometers)
Detection Info
Sample Notes
0.35 mg/mL of USP Abacavir Sulfate RS and 0.15 mg/mL of USP Lamivudine RS in 0.1N hydrochloric acid. Sonicate to dissolve prior to final dilution. Pass through a Nylon filter (Clarify Syringe filter PN: AF8-7707-12)
Order Items Used in This Application
- 1. Lamivudine
- 2. Abacavir
-OEChem-05151001052D<br><br> 26 27 0 1 0 0 0 0 0999 V2000<br> 3.2320 -1.8123 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0<br> 4.5411 -0.8613 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0<br> 4.4131 -3.5349 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0<br> 2.0000 0.7265 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0<br> 3.7320 0.7265 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0<br> 2.8660 2.2265 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0<br> 3.7320 3.7265 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0<br> 3.7320 -0.2735 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0<br> 2.9230 -0.8613 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 4.2320 -1.8123 0.0000 C 0 0 1 0 0 0 0 0 0 0 0 0<br> 4.8198 -2.6214 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 4.5981 1.2265 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 2.8660 1.2265 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 4.5981 2.2265 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 3.7320 2.7265 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0<br> 4.2845 0.0080 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 2.6130 -0.3244 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 2.3566 -1.1135 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 4.8444 -1.7154 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 5.3338 -2.9681 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 5.2505 -2.1754 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 5.1350 0.9165 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 5.1350 2.5365 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 4.7775 -4.0365 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 4.2690 4.0365 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 3.1951 4.0365 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0<br> 1 9 1 0 0 0 0<br> 1 10 1 0 0 0 0<br> 2 8 1 0 0 0 0<br> 2 10 1 0 0 0 0<br> 3 11 1 0 0 0 0<br> 3 24 1 0 0 0 0<br> 4 13 2 0 0 0 0<br> 8 5 1 1 0 0 0<br> 5 12 1 0 0 0 0<br> 5 13 1 0 0 0 0<br> 6 13 1 0 0 0 0<br> 6 15 2 0 0 0 0<br> 7 15 1 0 0 0 0<br> 7 25 1 0 0 0 0<br> 7 26 1 0 0 0 0<br> 8 9 1 0 0 0 0<br> 8 16 1 0 0 0 0<br> 9 17 1 0 0 0 0<br> 9 18 1 0 0 0 0<br> 10 11 1 1 0 0 0<br> 10 19 1 0 0 0 0<br> 11 20 1 0 0 0 0<br> 11 21 1 0 0 0 0<br> 12 14 2 0 0 0 0<br> 12 22 1 0 0 0 0<br> 14 15 1 0 0 0 0<br> 14 23 1 0 0 0 0<br>M END
Compound Name
Lamivudine
CID
60825
Molecular Formula
C8H11N3O3S
Molecular Weight
229
No. Hydrogen Bond Acceptors
4
No. Hydrogen Bond Donors
2
Similar Applications
Reversed Phase
USP Abacavir and Lamivudine Tablets - Assay (Standard Solution)
Kinetex 2.6 µm EVO C18 100 Å, LC Column 100 x 4.6 mm, EA
28078
Reversed Phase
USP Abacavir and Lamivudine Tablets - Assay (Standard Solution)
Luna Omega 3 µm C18 100 Å, LC Column 150 x 4.6 mm, Ea
28077
USP Abacavir and Lamivudine Tablets - Assay (Standard solution xterra)
28076
Reversed Phase
USP Abacavir and Lamivudine Tablets - Assay (System Suitability Solution)
Kinetex 2.6 µm EVO C18 100 Å, LC Column 100 x 4.6 mm, EA
28075
Reversed Phase
USP Abacavir and Lamivudine Tablets - Assay (System Suitability Solution)
Luna Omega 3 µm C18 100 Å, LC Column 150 x 4.6 mm, Ea
28074
USP Abacavir and Lamivudine Tablets - Assay (System suitability solution xterra)
28073
Reversed Phase
Ph. Eur. Monograph 2217: Lamivudine Related substances - Method 7 on Luna™ Omega 1.6 µm C18, 100 x 2.1 mm column
Luna Omega 1.6µm C18 100Å, LC Column 100 x 2.1 mm, EA
27634
Reversed Phase
Ph. Eur. Monograph 2217: Lamivudine Related substances - Method 6 on Luna™ Omega 1.6 µm C18, 100 x 2.1 mm column
Luna Omega 1.6µm C18 100Å, LC Column 100 x 2.1 mm, EA
27633
Reversed Phase
Ph. Eur. Monograph 2217: Lamivudine Related substances - Method 5 on Kinetex™ 2.6 µm C18, 150 x 3.0 mm column
Kinetex 2.6 µm C18 100 Å, LC Column 150 x 3 mm, Ea
27632
Reversed Phase
Ph. Eur. Monograph 2217: Lamivudine Related substances - Method 4 on Kinetex™ 2.6 µm C18, 150 x 3.0 mm column
Kinetex 2.6 µm C18 100 Å, LC Column 150 x 3 mm, Ea
27631
Reversed Phase
Ph. Eur. Monograph 2217: Lamivudine Related substances - Method 3 on Luna™ Omega 3 µm C18, 150 x 4.6 mm column
Luna Omega 3 µm C18 100 Å, LC Column 150 x 4.6 mm, Ea
27630
Reversed Phase
Ph. Eur. Monograph 2217: Lamivudine Related substances - Method 2 on Luna™ Omega 3 µm C18, 150 x 4.6 mm column
Luna Omega 3 µm C18 100 Å, LC Column 150 x 4.6 mm, Ea
27629
Reversed Phase
Ph. Eur. Monograph 2217: Lamivudine Related substances - Method 1 on Kinetex™ 5 µm C18, 250 x 4.6 mm column
Kinetex 5 µm C18 100 Å, LC Column 250 x 4.6 mm, Ea
27628
Reversed Phase
Ph. Eur. Monograph 2217: Lamivudine Related substances - Method 1 on Luna™ Omega 5 µm C18, 250 x 4.6 mm column
Luna Omega 5 µm C18 100 Å, LC Column 250 x 4.6 mm, Ea
27627
Ph. Eur. Monograph 2217: Lamivudine Related substances - Method 1 on Hypersil™ BDS 5 µm C18, 250 x 4.6 mm column
27626
Reversed Phase
IP Lamivudine Reference Solution C on Kinetex® 5µm C18, 250 x 4.6 mm LC/UV
Kinetex 5 µm C18 100 Å, LC Column 250 x 4.6 mm, Ea
27581
Reversed Phase
IP Lamivudine Reference Solution C on Luna® Omega 5µm C18, 250 x 4.6 mmLC/UV
Luna Omega 5 µm C18 100 Å, LC Column 250 x 4.6 mm, Ea
27580